Department of Nephrology and Transplantation, University Hospitals Birmingham, Birmingham, United Kingdom.
School of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
Transpl Int. 2024 Mar 11;37:12559. doi: 10.3389/ti.2024.12559. eCollection 2024.
The aim of this analysis was to explore mortality outcomes for kidney transplant candidates receiving older living donor kidneys (age ≥60 years) versus younger deceased donors or remaining on dialysis. From 2000 to 2019, all patients on dialysis listed for their first kidney-alone transplant were included in a retrospective cohort analysis of UK transplant registry data. The primary outcome was all-cause mortality, with survival analysis conducted by intention-to-treat principle. Time-to-death from listing was modelled using nonproportional hazard Cox regression models with transplantation handled as a time-dependent covariate. A total of 32,978 waitlisted kidney failure patients formed the primary study cohort, of whom 18,796 (58.5%) received a kidney transplant (1,557 older living donor kidneys and 18,062 standard criteria donor kidneys). Older living donor kidney transplantation constituted only 17.0% of all living donor kidney transplant activity (overall cohort; = 9,140). Recipients of older living donor kidneys had reduced all-cause mortality compared to receiving SCD kidneys (HR 0.904, 95% CI 0.845-0.967, = 0.003) and much lower all-cause mortality versus remaining on the waiting list (HR 0.160, 95% CI 0.149-0.172, < 0.001). Older living kidney donors should be actively explored to expand the living donor kidney pool and are an excellent treatment option for waitlisted kidney transplant candidates.
本分析旨在探讨接受老年活体供肾(年龄≥60 岁)、年轻已故供者肾或继续透析的肾移植候选者的死亡率结局。2000 年至 2019 年,所有列入首次单独肾移植名单的透析患者均纳入英国移植登记数据的回顾性队列分析。主要结局是全因死亡率,采用意向治疗原则进行生存分析。采用非比例风险 Cox 回归模型对从列入名单到死亡的时间进行建模,将移植作为时间相关协变量进行处理。共有 32978 名列入名单的肾衰竭患者构成了主要研究队列,其中 18796 名(58.5%)接受了肾移植(1557 例老年活体供肾和 18062 例标准标准供肾)。老年活体供肾移植仅占所有活体供肾移植活动的 17.0%(总队列; = 9140)。与接受 SCD 肾脏的患者相比,接受老年活体供肾的患者全因死亡率降低(HR 0.904,95%CI 0.845-0.967, = 0.003),与继续等待名单相比,全因死亡率低得多(HR 0.160,95%CI 0.149-0.172, < 0.001)。应积极探索老年活体供肾者,以扩大活体供肾库,为列入名单的肾移植候选者提供极好的治疗选择。